Recent Posts

Checkpoint inhibitor therapy more economical, safe than CAR T cells in pediatric leukemia

Novel advances in the use of checkpoint inhibitors – such as an anti-PD1 or anti-PDL1 – to treat pediatric leukemia may result in the ability to eliminate the use of CAR T-cell therapy in that patient population in the future, according to Donald Durden, MD, PhD, vice chair for research at UC San Diego’s Department of Pediatrics and associate director for pediatric oncology at the Moores UCSD Cancer Center.

Read more here: http://www.healio.com/hematology-oncology/leukemia/news/online/%7Be0935e2e-d5ed-4299-a6eb-4a7bfa4ea252%7D/checkpoint-inhibitor-therapy-more-economical-safe-than-car-t-cells-in-pediatric-leukemia